European regulators have recommended approval of Merck’s multiple sclerosis drug Rebif for additional uses.
The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Rebif to be used for patients who have shown an early sign of multiple sclerosis and are at high risk of developing the disease.
Recommendations for marketing approval by the London-based CHMP are normally endorsed by the European Commission within a couple of months.
Multiple sclerosis, which affects 2.5 million people worldwide, is a chronic and progressive disease that attacks the central nervous system.
Source: Irish Times
..
===========================================================
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Help us to educate $ DONATE NOW PLEASE $
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews